Tempus AI, Inc. Class A (NASDAQ:TEM) is expanding its precision-medicine footprint: after rolling out the 27-gene RightMed plus DPYD and UGT1A1 OneOme panel nationally with <5-day results, TEM agreed to acquire another company in an all-stock deal (0.3356 cap) or up to 50% cash, closing 2026–2027.
Previous Week Recap
- Tempus AI, Inc. Class A All-Stock Deal Cap 0.3356: Tempus AI (TEM) to buy company in all-stock deal with floating exchange ratio capped at 0.3356; Tempus can instead pay up to 50% cash. Closing expected late 2026–early 2027, pending approvals.
- Tempus AI, Inc. Class A OneOme National Rollout: Tempus AI (TEM) rolled out OneOme pharmacogenomics nationally after its 2025 OneOme buy; offering 27-gene RightMed plus DPYD and UGT1A1 tests, <5-day results, integrated with Tempus care platform.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.